ArticleThe Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale2026
Analysis of HIV Drug Resistance Mutations Along With Treatment Outcomes of Efavirenz-Based Regimens in Patients With V179D/E Mutations in Guangzhou, China.
Article in The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Analysis of HIV Drug Resistance Mutations Along With Treatment Outcomes of Efavirenz-Based Regimens in Patients With V179D/E Mutations in Guangzhou, China.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: To analyze the prevalence of human immunodeficiency virus type 1 (HIV-1) drug resistance mutations (DRMs) and compare the therapeutic outcomes of different antiretroviral treatment regimens in newly diagnosed HIV-1-infected patients with the V179D/E mutation. Methods: This study included newly diagnosed HIV-1-infected individuals in Guangzhou from 2020 to 2024. Peripheral venous blood samples were collected, and viral RNA was extracted. The Results: Of 740 enrolled patients who underwent baseline resistance testing, 198 (26.76%) harbored DRMs, of whom 59 (7.97%) exhibited pretreatment drug resistance (PDR). The predominant HIV subtypes were CRF07_BC and CRF01_AE. Non-nucleoside reverse transcriptase inhibitors (NNRTIs) were associated with a DRM prevalence rate of 22.16% ( Conclusion: The prevalence of DRMs in newly diagnosed HIV-1-infected individuals in Guangzhou associated with NNRTIs is 22.16%, primarily driven by the V179D/E mutation. EFV-based treatments were associated with higher cumulative virological failure rates in patients with V179D/E mutation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.